Eli Lilly and Company has announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.

Louis J. Aronne, MD, FACP, DABOM, Founder and Chair Emeritus of the American Board of Obesity Medicine, Former President of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Consultant, Lilly, said, "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made. These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy."

In SURMOUNT-MAINTAIN, both Zepbound MTD and Zepbound 5 mg met the primary and all key secondary endpoints, demonstrating weight-loss maintenance after 60-weeks of initial treatment with Zepbound MTD. The primary endpoint was to demonstrate that continuation of Zepbound either at a reduced 5 mg dose or at MTD was superior to placebo in percent change in body weight at week 112. At week 112, participants continuing treatment with Zepbound MTD preserved all of their prior weight loss, while dose reduction to 5 mg maintained all but 5.6 kg on average.

ATTAIN-MAINTAIN demonstrated that switching to Foundayo also supported long-term weight maintenance, meeting the primary and all key secondary endpoints using both the efficacy estimand and treatment-regimen estimand. The primary endpoint was to demonstrate that Foundayo was superior to placebo in percent maintenance of body weight reduction, among SURMOUNT-5 participants who previously reached a body weight plateau. At week 52, participants who switched from Wegovy MTD to Foundayo maintained all but 0.9 kg of their previously achieved weight loss, while those who switched from Zepbound MTD to Foundayo maintained all but 5.0 kg.